Related Experiment Video

Updated: May 16, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

Data sources for heart failure comparative effectiveness research

Ying Xian1, Bradley G Hammill, Lesley H Curtis

  • 1Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC 27715, USA.

Heart Failure Clinics
|November 22, 2012
PubMed

Insights

Comparative Effectiveness Research (CER) for heart failure relies on diverse data. Linking clinical registries with administrative or EHR data is crucial for robust, real-world evidence and improved patient outcomes.

Area of Science:

  • Health Services Research
  • Biomedical Informatics
  • Comparative Effectiveness Research

Background:

  • Existing data sources for heart failure research present limitations for CER.
  • Clinical registries offer detailed real-world data but lack longitudinal follow-up.
  • Large administrative datasets provide broad longitudinal coverage but lack clinical detail.

Purpose of the Study:

  • To evaluate the advantages and disadvantages of various data sources for heart failure CER.
  • To highlight the potential of linking diverse datasets for comprehensive CER.
  • To emphasize the need for improved data infrastructure for patient-centered CER.

Main Methods:

  • Review of existing data sources for heart failure research.
  • Discussion of the characteristics of clinical registries and administrative datasets.
  • Exploration of the concept of linking disparate data sources.

Main Results:

  • No single data source is ideal for heart failure CER.
  • Linking clinical registries with administrative or EHR databases shows significant promise.
  • Recommendations for advancing data infrastructure for CER are provided.

Conclusions:

  • Integrating diverse data sources is essential for robust heart failure CER.
  • Further development of data linking infrastructure is a priority.
  • Patient-centered CER requires comprehensive and scientifically sound data resources.

More Related Videos

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...